Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Lymphoma
Interventions
BIOLOGICAL

filgrastim

480 mcg beginning day +5

DRUG

busulfan

11.2 mg/kg; 0.8 mg/kg IV q6h X 14 doses

DRUG

cyclophosphamide

60 mg/kg IV over 2 hours x 2 days

DRUG

etoposide

60 mg/kg, IV

DRUG

melphalan

150mg/m2 in NS at a concentration of 0.4mg/cc infused over 60 minutes.

PROCEDURE

autologous-autologous tandem hematopoietic stem cell transplantation

autologous-autologous tandem hematopoietic stem cell transplantation

RADIATION

radiation therapy

radiation therapy

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00265889 - Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter